The aim is to counter MRK’s pursuit of the CKD segment of the HCV market (#msg-112517136). I.e. ABBV plans to fight for every HCV market segment (with the possible exception of prior treatment failures on Incivek/Victrelis).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.